Articles tagged with Drug Studies
Imetelstat, a telomerase inhibitor, successfully treated anaemia in MDS patients for up to one year, reducing the need for red blood cell transfusions. The drug offers a novel mechanism of action for patients with lower-risk MDS who do not respond to standard treatment.
A world-first human trial shows that a commonly prescribed rheumatoid arthritis drug can safely and effectively preserve the body's own insulin production and suppress the progression of type 1 diabetes. The drug, baricitinib, was found to be effective in maintaining insulin production in people who initiated treatment within 100 days ...
Researchers found that statin therapy reduced mortality and disease risk among people with chronic kidney disease and frailty, regardless of age-related health conditions. The studies provide additional context to the debate about initiating statin use in people at high risk for heart disease.
A Phase 2 clinical trial will study the effectiveness of a monoclonal antibody treatment, TS23, in reducing brain injury and improving outcomes for patients with acute ischemic stroke. The SISTER study aims to provide new hope for treatment and recovery for patients where time and access may have been limited.
Researchers discovered the PanH enzyme, which catalyzes the selective epoxidation of cyclohexenones, a challenging reaction to achieve through chemical synthesis. The study shows that this enzyme can produce a large library of substances with improved and more specific activities in biomedical research.
Researchers at Johns Hopkins Medicine discovered a promising experimental drug combination that reduces the size of peripheral nerve sheath tumors in mice and increases survival rates. The combination blocks glutamine metabolism and purine recycling, producing a better anti-tumor response with less toxicity.
The Lung-MAP trial has demonstrated the potential of public-private partnerships in clinical research, increasing access to new treatment options for patients with lung cancer. The unique partnership between academia, advocacy, federal agencies, and industry has led to a more representative patient group being enrolled in clinical trials.
A new study using smartphone app data found certain medications like triptans, ergots, and anti-emetics to be two to five times more effective than ibuprofen for migraine treatment. Researchers analyzed over 3 million treatment attempts with various medications, including NSAIDs and combination therapies.
A two-year study found that participants who received personalized coaching experienced a modest boost in cognitive testing, measuring a 74% improvement over the non-intervention group. Additionally, improvements were noted between the two groups in measurements of risk factors and quality of life.
Two large studies found that people with ADHD who take medication for a long time and in higher doses are at a higher risk of developing some cardiovascular diseases. The highest rate of discontinuation occurred among 18 to 19-year-olds, highlighting the need for better transition to adult psychiatry services.
A new study will compare two treatment regimens: one using non-opioid medication and another with a low-dose opioid to determine the safest and most effective way to treat pain in adolescents and young adults recovering from common outpatient surgeries. The CARES for Kids study aims to generate evidence-based information on this topic.
A new clinical trial has shown that a stem cell-based device can reduce the amount of insulin required for some participants with Type 1 diabetes. The device, developed by ViaCyte, aims to replace the insulin-producing beta cells that people with the condition lack.
Researchers at UCSF and Kaiser Permanente Washington found that participants who received personalized coaching experienced a 74% improvement in cognitive testing compared to non-intervention participants. The study also showed improvements in risk factors and quality of life, with modest but significant increases in cognitive function.
Researchers at University of California - San Francisco find that sense of taste signals brain to slow down eating. Using advanced techniques, they recorded brain activity in awake mice and found PRLH neurons controlled by mouth signals when eating normally, not gut signals as previously thought.
A new study at the University of Turku discovered that plixorafenib inhibits multiple signaling pathways in cutaneous squamous cell carcinoma, showing promise for treatment. The drug was originally developed for melanoma and lung cancer, but its effectiveness against cSCC is significant.
Researchers found that immunomodulatory drugs used to treat rheumatoid arthritis can reduce the risk of autoimmune thyroid diseases. Patients treated with these drugs had a 46% lower risk of developing an autoimmune thyroid disease compared to those without rheumatoid arthritis.
A phase 2 trial found that durvalumab is safe and may benefit overall survival in non-small cell lung cancer patients with borderline performance status. The study also showed stable quality of life and a lower incidence of severe treatment-related adverse events compared to platinum doublet chemotherapy.
Researchers found that three medicines - CGRP inhibitors, amitriptyline, and simvastatin - had a better preventive effect on migraine than traditional beta blockers. This discovery could have significant implications for healthcare costs, as the cheaper alternatives may offer similar treatment effects.
Scientists at Texas Biomedical Research Institute found a promising cancer therapy also effectively reduces TB growth, even for drug-resistant bacteria. The therapy combines MCL-1 and BCL-2 inhibitors with antibiotics to control TB up to 98%.
Researchers at Purdue University have developed a novel cancer immunotherapy compound that targets the enzyme TC-PTP, found in both cancer cells and T cells. Deleting this enzyme promotes antigen presentation, alerting the immune system to tumor cells, while stimulating T-cell activation enhances their ability to fight and destroy tumors.
A new study suggests that genetic testing for depression could lead to significant cost savings and improved patient outcomes. The test, known as pharmacogenomic testing, can help match patients with medications that are more likely to be effective and cause fewer side effects.
Researchers from Mass General Brigham found that patients experiencing virologic rebound after treatment may remain contagious. The study suggests that individuals shed live virus when experiencing a rebound, implying the potential for transmission after initially recovering from the virus.
A three-year intensive treatment strategy to lower systolic blood pressure below 120mmHg significantly reduced cardiovascular events, including heart attack, stroke, and death, compared to standard treatment. The study found that participants in the intensive group experienced fewer major vascular events and deaths over a two-year period.
A 20% reduction in major adverse cardiovascular events has been observed for patients with obesity but no history of diabetes taking semaglutide. This study marks a significant milestone, demonstrating the cardiovascular benefits of semaglutide beyond its weight loss effects.
Researchers found that people with overweight or obesity who took semaglutide for over 3 years had a 20% lower risk of heart attack, stroke, or death from cardiovascular disease. The study showed significant weight loss and improved cardiovascular outcomes in adults without diabetes.
Researchers found that abelacimab, a Factor XI inhibitor, reduced bleeding compared to rivaroxaban in patients with atrial fibrillation. The study showed significant reduction in hospitalization due to bleeding and almost eliminated gastrointestinal bleeding.
A new study suggests that a PCSK9 inhibitor given every 1-3 months may effectively lower bad cholesterol levels in people with non-genetic hypercholesterolemia. The medication, recaticimab, showed similar effectiveness and safety as other PCSK9 inhibitors when administered less frequently.
A randomized controlled trial suggests that a more liberal approach to red blood cell transfusions for heart attack patients with anemia may benefit outcomes without significant risk. The study found no statistically significant difference between two transfusion strategies, but results suggest a possible benefit of liberal transfusions.
A single dose of zilebesiran safely and effectively lowered systolic blood pressure in people with mild-to-moderate high blood pressure for up to six months. The study found significant reductions in daytime and nighttime systolic blood pressure, as well as low rates of adverse events.
A new anti-clotting medication, abelacimab, has significantly reduced bleeding among people with atrial fibrillation who are at risk of stroke. The AZALEA-TIMI 71 trial found that abelacimab substantially reduced bleeding compared to the current standard of care use of direct-acting oral anticoagulants.
A study found that pregnant women with high blood pressure who received tight blood pressure control immediately after pregnancy had lower blood pressure levels and improved cardiac function compared to those with usual care. This could lead to a reduced risk of cardiovascular disease, including heart attacks and strokes.
A phase 4 clinical trial found that apixaban, an anti-clotting medication, reduced the rate of stroke and blood clots in adults with implanted heart devices experiencing short bouts of asymptomatic, irregular heart rhythms. The study suggests that these individuals may benefit from receiving an anticoagulant.
A single infusion of CRISPR-based gene-editing therapy significantly reduced LDL cholesterol levels in people with heterozygous familial hypercholesterolemia, a condition that increases heart attack risk. The treatment has shown potential as a long-term or permanent option for high LDL-C control.
The ORBITA-2 trial found that stenting improves symptoms compared to a placebo procedure, providing evidence-based treatment for stable chest pain. The study suggests updating guidelines for stable coronary artery disease and offers patients and medical teams two treatment strategies with similar benefits.
A four-year blood-pressure intervention significantly reduced the risk of developing dementia among adults with high blood pressure, compared to those who received usual care. The study found that lowering systolic blood pressure to less than 130 mm Hg and diastolic blood pressure to less than 80 mm Hg reduced dementia risk.
A new therapeutic, lepodisiran, has shown promising results in reducing lipoprotein(a) levels to undetectable levels for nearly one year. The study found that the medication is safe and effective in lowering Lp(a) levels by more than 94%.
A recent clinical trial found that semaglutide significantly reduced cardiovascular events in adults with overweight or obesity who do not have diabetes. The medication was shown to lower the risk of death from cardiovascular causes, nonfatal heart attacks, and strokes by 20% compared to placebo.
Researchers at the University of Illinois have developed a new antifungal molecule that targets fungal cells without harming human kidney cells or other tissues. The molecule, dubbed AM-2-19, has shown significant efficacy against various fungal infections in vitro and in vivo studies.
A study published in Nature Communications reveals that the 'salience network' in the brain is uniquely activated by intravenous drug use, which may be associated with higher addiction rates and faster relief from withdrawal. This finding could lead to the development of new therapies for substance use disorders.
Patients with HER2-positive breast cancer that has spread to other parts of the body survive for longer if treated with pyrotinib. The new drug targets proteins involved in HER2-positive breast cancer and shows a 22% reduction in risk of death compared to lapatinib.
A recent study found that transient inflammatory pain causes persistent mitochondrial and metabolic disturbances in sensory neurons, leading to failure in pain resolution. Targeting the cellular redox balance prevents and treats chronic inflammatory pain in rodents.
A new study has found that tumor necrosis factor inhibitors, commonly used for inflammatory arthritis, are not associated with poor pregnancy outcomes. Women who continued treatment had lower risks of severe infections postpartum compared to those who stopped. The results provide reassuring data on the use of TNF blockers during pregna...
A phase 1 trial of the radiopharmaceutical 225AC-J591 demonstrated promising antitumor activity against advanced metastatic prostate cancer, reducing PSA levels by at least half for 47% of patients. The treatment was well-tolerated, with only temporary low blood cell count side effects.
A small clinical trial led by the University of Houston demonstrates Riluzole's effectiveness in improving functionality in people with acute spinal cord injuries. The study used an SCI-specific biomarker to show how Riluzole reduces neuron cell damage and improves motor abilities.
A multicenter, retrospective study of Japanese patients treated with JAK inhibitors found impressive remission rates and low disease activity. The study's results contradict previous concerns about the effectiveness of these drugs, suggesting they may be a viable option for patients with other health problems.
Scientists at the University of Cambridge identified a molecule that plays a key role in triggering inflammation in response to harmful materials. The researchers found that inhibiting this molecule, PLK1, can prevent overly aggressive inflammatory responses in conditions like gout and heart diseases.
A large-scale study found that metformin can reduce weight gain and increase adherence to treatment in youth with bipolar disorder. The medication, typically used for Type 2 diabetes, was effective in preventing weight gain and showed promise as a potential solution to this common side effect of SGAs.
A new international clinical trial found that a drug candidate is highly effective in treating Acanthamoeba keratitis with medical cure rates of 87%, reducing the risk of poor visual outcomes and surgery. The treatment, low concentration polihexanide (PHMB 0.08%), follows a novel and evidence-based protocol.
A UCLA-led study shows datopotamab deruxtecan, a Trop-2 directed antibody-drug conjugate, significantly improves progression-free survival in patients with metastatic non-small cell lung cancer. The treatment primarily benefits patients with non-squamous tumors, reducing disease progression and improving overall survival.
A year-long clinical trial found sustained remission of polymyalgia rheumatica in 28% of patients taking sarilumab, compared to 10% of those on placebo. The treatment showed promise in reducing relapse and improving outcomes for patients tapering their steroid medication.
A brain-computer interface (BCI) has been successfully used to restore control of home devices for a patient with ALS, allowing the individual to navigate a communication board and smart devices without recalibration. The BCI device was implanted on the surface of the brain areas responsible for speech and upper limb function, enabling...
A global platform study has released results on the use of simvastatin to treat severely ill patients with COVID-19, showing a high probability of improving outcomes. In contrast, high-dose vitamin C was found to be ineffective and potentially harmful in critically ill patients, suggesting its use should be discontinued.
A clinical trial has shown that combining chemotherapy with immunotherapy nivolumab significantly improved outcomes in patients with advanced bladder cancer. The study found nearly twice as many patients with no evidence of disease after treatment, and a median complete response of 37.1 months.
A new drug, cabozantinib, has shown positive results in a clinical trial involving patients with advanced neuroendocrine tumors. The study found that patients treated with cabozantinib survived significantly longer without their disease worsening compared to those who received a placebo. This novel treatment strategy targets angiogenes...
A phase III pivotal trial evaluating cabozantinib in advanced neuroendocrine tumors demonstrated significant improvements in median progression-free survival (PFS) compared to placebo. The study met its primary objective for both cohorts of patients, providing encouraging news for those with progressive disease.
A new study found that muscle dysmorphia symptoms are associated with increased risk of suicidal thoughts and behaviors among Canadian adolescents and young adults. The study highlights the need for greater awareness and proper identification of muscle dysmorphia symptoms to prevent future suicidal ideation and suicide planning.
A new cancer immunotherapy that targets two immune-evading tumor tactics has shown promising results in an early clinical trial. The drug, tebotelimab, blocks both PD-1 and LAG-3 proteins, leading to a double-digit response rate in patients with advanced solid tumors or blood cancers.
Scientists have developed a technique to restore the function of human-derived GPCR proteins in yeast cells, which could accelerate research and lead to more effective treatments. The approach, using error-prone polymerase chain reaction, introduces random mutations that enhance protein stability and function.
A study published in Psychological Medicine found that the widely prescribed sedative alprazolam XR may be less effective than believed, with publication bias inflating its efficacy by over 40%. This suggests caution for patients and clinicians starting a prescription for panic disorder.
The study found that precision oncology therapies require genomic biomarker screening for patient selection and have expanded over the years. The analysis showed a slow expansion in approvals from 1998 to 2017 and a rapid increase from 2017 to 2022, with 86 out of 198 approved drugs classified as precision oncology drugs.